NCT06690905CompletedPhase 4
Evaluation of the Achievement of a Pharmacodynamic Target of Piperacillin-Tazobactam for the Population With Obesity
Evaluation of the Achievement of a Pharmacodynamic Target of Piperacillin-Tazobactam for the Population With Obesity: an Open Randomized Controlled Feasibility Study
Source: ClinicalTrials.gov · Last updated 17 Mar 2026
Brief summary (registry, in English)
This study aims to evaluate the feasibility of an open randomized controlled study which would assess the proportion patients with obesity who will have a favorable pharmacodynamic parameter (i.e. fT\> 100% MIC) after 24 hours of piperacillin-tazobactam administered as a prolonged intermittent infusion compared to a standard infusion.
- Status (registry)
- Completed
- Phase (registry)
- Phase 4
- Study type
- Interventional
- Enrollment
- 45 (actual)
- First submitted
- 12 Nov 2024
- Start date
- Feb 2025
- Primary completion date
- Sept 2025
- Lead sponsor
- CR-CSSS Champlain-Charles-Le Moyne
- Diseases
- Obesity
- NCT number
- NCT06690905
What you commit to
- Study type: Interventional · Phase 4
- Participants enrolled: 45
- From Feb 2025 to the primary completion date, Sept 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Patients with renal replacement therapy (hemodialysis, peritoneal dialysis, continuous venovenous hemodiafiltration)
- History of seizures or epilepsy, active seizures or epilepsy treated with antiepileptic drug therapy
Other illness
- Documented allergy to beta-lactams of the penicillin class
Other
- Pregnancy
- Patients on prolonged intermittent infusion or continuous infusion of piperacillin-tazobactam before randomization
Who the study is looking for
- Adults (18 years and older)
- Patients hospitalized at Hôpital Charles-Le Moyne
- Obesity (as defined by a body mass index of ≥ 30 kg/m\^2)
- Piperacillin-tazobactam prescription initiated within last 24 hours
- Planned duration of piperacillin-tazobactam of 24 hours or more
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Hopital Charles Le Moyne Coordinator of this site? Confirm its status | Greenfield Park | Canada | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.